NEW
YORK, June 25, 2024 /PRNewswire/ -- The global
hematopoietic stem cells transplantation (HSCT) market size is
estimated to grow by USD 2.58 billion
from 2024-2028, according to Technavio. The market is estimated to
grow at a CAGR of 6.64% during the forecast
period. Availability of technologically advanced
equipment is driving market growth, with a trend towards growing
demand for personalized medicine. However, high cost of HSCT poses
a challenge. Key market players include AllCells Corp., Athersys
Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc., Cellular
Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd., Lineage
Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co. Ltd., Merck
and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics Inc., Sanofi
SA, Sartorius CellGenix GmbH, Taiga Biotechnologies Inc., Takeda
Pharmaceutical Co. Ltd., Talaris Therapeutics Inc., and
ThermoGenesis Holdings Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Application (Bone
marrow transplant, Peripheral blood stem cell transplant, and Cord
blood transplant), Type (Autologous HSCT and Allogeneic HSCT), and
Geography (North America, Europe, Asia, and Rest of World
(ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
AllCells Corp.,
Athersys Inc., Beike Biotechnology Co. Ltd., bluebird bio Inc.,
Cellular Biomedicine Group Inc., FUJIFILM Corp., Gamida Cell Ltd.,
Lineage Cell Therapeutics Inc., Lonza Group Ltd., MEDIPOST Co.
Ltd., Merck and Co. Inc., Mesoblast Ltd., Pluristem Therapeutics
Inc., Sanofi SA, Sartorius CellGenix GmbH, Taiga Biotechnologies
Inc., Takeda Pharmaceutical Co. Ltd., Talaris Therapeutics Inc.,
and ThermoGenesis Holdings Inc.
|
Key Market Trends Fueling Growth
The hematopoietic stem cells transplantation (HSCT) market is
experiencing growth due to the use of mesenchymal stem cells (MSC)
in the process. MSC, found in bone marrow, offer benefits such as a
low risk of immune rejection, no need for embryonic stem cells, and
minimal requirement for anti-rejection drugs. These cells also
possess immunosuppressive properties, improving engraftment rates
and reducing the risk of graft-versus-host disease (GvHD). Despite
the side effects of immunosuppressive therapy, MSC's benefits make
HSCT more effective for treating hematological malignancies and
inflammatory diseases.
The Hematopoietic Stem Cells Transplantation (HSCT) market is
experiencing significant growth due to the increasing demand for
advanced treatments in various diseases. The use of HSCT in the
treatment of hematological malignancies and genetic disorders is on
the rise. The market is driven by the development of new
technologies and therapies, such as Gamida Cell's CAR-T cell
therapy and Cellectis' Allogeneic CAR-T therapy. Additionally, the
growing awareness and acceptance of HSCT as a viable treatment
option are contributing to market growth. The market is expected to
continue its upward trend in the coming years, with key players
focusing on innovation and expansion to meet the increasing
demand.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The HSCT market is projected to expand due to technological
advancements, new indications, and alternative graft sources.
However, the high cost of transplants, which increases with
co-morbidities, acute GvDH, and lengthy hospital stays,
hinders market growth. Patients may need extended stays near
hospitals for monitoring, further increasing costs. These factors
limit adoption and market expansion during the forecast
period.
- The Hematopoietic Stem Cells Transplantation (HSCT) market
faces several challenges. These include the high cost of procedures
and the need for donor matching. Additionally, the complexity of
the process and the risk of graft-versus-host disease require
advanced technology and skilled professionals. Furthermore, the
lack of awareness and understanding about HSCT among potential
patients and healthcare providers can hinder market growth. The use
of cord blood and haploidentical transplants offers potential
solutions to some of these challenges, but also present new ones,
such as ethical considerations and logistical complexities.
Overall, the HSCT market requires continued innovation and
investment to address these challenges and make this life-saving
treatment more accessible and affordable for all.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This hematopoietic stem cells transplantation (HSCT) market
report extensively covers market segmentation by
- Application
- 1.1 Bone marrow transplant
- 1.2 Peripheral blood stem cell transplant
- 1.3 Cord blood transplant
- Type
- 2.1 Autologous HSCT
- 2.2 Allogeneic HSCT
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Bone marrow transplant- The Hematopoietic Stem
Cells Transplantation (HSCT) market experiences growth due to the
increasing need for bone marrow transplants. These procedures
replace dysfunctional bone marrow with healthy stem cells,
benefiting patients with various disorders such as acute and
chronic leukemia, adrenoleukodystrophy, aplastic anemia, and bone
marrow failure syndromes. The demand for bone marrow transplants
rises as they improve prospects of cure and survival, leading to
market expansion throughout the forecast period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
The Hematopoietic Stem Cells Transplantation (HSCT) market
encompasses the use of autologous and allogeneic transplantation
procedures for the treatment of hematological disorders such as
leukemia, lymphoma, and lymphoproliferative disorders. Bone marrow
transplants and cord blood are common sources of hematopoietic stem
cells. Allogeneic transplant therapy involves the use of donor
cells, while autologous transplant therapy utilizes a patient's own
cells. Magenta Biosciences and Gamida Cell are involved in the
development of stem cell-based medicines. Clinical trials explore
new transplantation procedures and therapies, including immune
cloaking and therapeutic cells. The prevalence of cancer,
particularly common cancers, drives healthcare expenditure in this
market. Inorganic growth strategies, such as acquisitions and
collaborations, are common in the industry. The HSCT market is of
significant importance in addressing public health emergencies,
including the ongoing COVID-19 pandemic.
Market Research Overview
The Hematopoietic Stem Cells Transplantation (HSCT) market
refers to the global trade of products, technologies, and services
related to the transplantation of hematopoietic stem cells. These
cells are essential for the production of new blood cells in the
body. HSCT is a medical procedure used to replace damaged or
destroyed cells in the bone marrow with healthy ones. The market
for HSCT is driven by the increasing prevalence of blood disorders,
such as leukemia, lymphoma, and aplastic anemia. Additionally,
advancements in stem cell research and technology are leading to
new applications and treatments, expanding the market further. The
HSCT market includes various components, such as stem cell sources,
collection and processing methods, and transplantation techniques.
The market is expected to grow significantly in the coming years
due to these factors.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Bone Marrow Transplant
- Peripheral Blood Stem Cell Transplant
- Cord Blood Transplant
- Type
-
- Autologous HSCT
- Allogeneic HSCT
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hematopoietic-stem-cells-transplantation-hsct-market-size-is-set-to-grow-by-usd-2-58-billion-from-2024-2028--availability-of-technologically-advanced-equipment-to-boost-the-market-growth-technavio-302181339.html
SOURCE Technavio